Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

D-085

Supelco

Dexamethasone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C22H29FO5
Número de CAS:
50-02-2
Peso molecular:
392.46
Número MDL:
MFCD00064136
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329798644
NACRES:
NA.24

grado

certified reference material

Nivel de calidad

300

Formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

Clave InChI

UREBDLICKHMUKA-CXSFZGCWSA-N

Información sobre el gen

human ... NR3C1(2908)

Descripción general

Dexamethasone is a potent glucocorticoid which acts as an anti-inflammatory and immunosuppressant for therapeutic treatments in many inflammatory and autoimmune conditions, oncology, and endocrine diseases such as Addison′s disease. Dexamethasone levels in serum or plasma are measured by LC-MS/MS for dexamethsaone suppression tests or monitoring dexamethsaone treatment regimens. This Certified Spiking Solution® is suitable for use as starting materials in the preparation of calibrators and controls for dexamethasone testing methods by LC-MS/MS.

Aplicación

  • Controlled drug delivery systems: Hydrogel microneedles incorporating dexamethasone demonstrate a programmed mesophase transition, optimizing the controlled release of drugs for therapeutic applications. This advancement in drug delivery technology illustrates the utility of dexamethasone solution in developing innovative pharmaceutical materials (Dawud et al., 2024).
  • Enhanced nasal drug administration: Bovine Serum Albumin nanoparticles, integrated with dexamethasone, highlight a novel gelling system designed to enhance nasal drug delivery. This research underscores the potential of dexamethasone solution in creating more effective and patient-friendly drug delivery modalities (Mardikasari et al., 2023).
  • Sustained-release formulations: The development of polyvinyl alcohol microparticles for the sustained release of dexamethasone via a coaxial microfluidic system demonstrates the critical role of dexamethasone solution in producing precision drug delivery systems that improve therapeutic efficacy and patient compliance (Abdi Majareh et al., 2023).
  • Topical drug delivery for ocular conditions: Dexamethasone-loaded chitosan nanoparticles were developed for topical application in a rabbit model of endotoxin-induced uveitis, indicating significant advancements in localized drug delivery systems using dexamethasone solutions. This application is particularly relevant in treating inflammatory eye diseases with enhanced drug delivery efficiency (Alkholief et al., 2023).

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Producto relacionado

Referencia del producto
Descripción
Precios

A-096

Aldosterone solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-106

Cortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-113

Cortisol-D4 (9,11,12, 12-D4) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-117

Corticosterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-061

11-Deoxycortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-062

21-Deoxycortisol solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-076

21-Deoxycortisol-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-078

11-Deoxycortisol-D5 (2,2,4,6,6-D5), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-085

17α-Hydroxyprogesterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-096

17α-Hydroxyprogesterone-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-100

17α-Hydroxyprogesterone-2,3,4-13C3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-069

Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

P-070

Progesterone-D9 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

C-160

Cortisone-13C3 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

C-159

Corticosterone-13C3 solution, 10 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

P-123

Prednisolone-13C3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

P-124

Prednisone-13C3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Shankar Swaminathan et al.
Journal of biomedical nanotechnology, 9(6), 998-1007 (2013-07-19)
Nanosponges (NS) were synthesized by crosslinking of beta cyclodextrins with diphenyl carbonate. It is a hyper-branched polymer with an ultra high encapsulation efficiency leading to formation of colloidal systems. Dexamethasone (DEX) on the other hand is a poorly soluble drug
Sara Bringhen et al.
Blood, 124(1), 63-69 (2014-05-24)
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who
Alice Pham et al.
Obstetrics and gynecology, 120(6), 1451-1458 (2012-11-22)
To estimate the beneficial and harmful effects of dexamethasone for prevention of postoperative nausea and vomiting in women undergoing laparoscopic gynecologic surgery. We searched the following bibliographic databases: MEDLINE (from 1946 to January 2012), Embase (from 1980 to 2012 week
N H Waldron et al.
British journal of anaesthesia, 110(2), 191-200 (2012-12-12)
The analgesic efficacy and adverse effects of a single perioperative dose of dexamethasone are unclear. We performed a systematic review to evaluate the impact of a single i.v. dose of dexamethasone on postoperative pain and explore adverse events associated with
Erich Piovan et al.
Cancer cell, 24(6), 766-776 (2013-12-03)
Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico